Company intelligence / Profile preview

DesignMedix

Portland, Oregon, United Statescrunchbase.com ↗

Ownership: Private
Development stage: Other

Overview

DesignMedix developed small molecule drugs targeting drug-resistant infectious diseases, with a lead antimalarial candidate (DM‑1157) reaching Phase 1 trials before the company ceased operations in March 2020. The pipeline also included another antimalarial series and an antibacterial program for severe diarrheal disease. No recent clinical results are available post-shutdown.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

DM1157

Beyond the preview

Go deeper on DesignMedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DesignMedix.

Explore the full profile